NATCO Pharma stock has declined 34% over six days due to disappointing Q3 FY25 results, including a 37.4% revenue drop and a ...

Natco Pharma shares nosedived today. Its results were impacted by a sharp decline in the export formulation business.

The stock plunged 10.80 per cent to hit a 52-week low of Rs 868.25. At this price, it has tumbled 28.63 per cent in two ...

Natco Pharma's Q3 earnings were heavily dented by a sharp drag in its export formulations segment, which accounted for 44 ...

Shares of Natco Pharma tumbled 19.86 per cent to hit a low of Rs 975. The stock saw high trading volume on BSE today.

Image Source : PIXABAY The counter opened gap down with a loss of 18.96 per cent.

The company reported a net profit of ₹1,324 crore, down 37.7% from the previous year's ₹2,127 crore. Natco Pharma shares are ...

Stock analysts noted Natco Pharma’s missed consensus Q3 estimates on both revenue and Ebitda margin fronts due to lack of ...

NATCO Pharma reported a 37.75% decline in Q3 FY2025 net profit, dropping to ₹132.4 crore due to a downturn in formulation ...

During the quarter, contribution from the export formulation business was lower; however, the company expects healthy ...

Natco Pharma Ltd shares tanked during the early trading session on Thursday, February 13, 2025, after it announced weak third ...

Thus far in the calendar year 2025, the Nifty Pharma index has slipped 11 per cent, as against 3.7 per cent fall in Nifty 50.